JP2013523705A5 - - Google Patents

Download PDF

Info

Publication number
JP2013523705A5
JP2013523705A5 JP2013501932A JP2013501932A JP2013523705A5 JP 2013523705 A5 JP2013523705 A5 JP 2013523705A5 JP 2013501932 A JP2013501932 A JP 2013501932A JP 2013501932 A JP2013501932 A JP 2013501932A JP 2013523705 A5 JP2013523705 A5 JP 2013523705A5
Authority
JP
Japan
Prior art keywords
ester
physiologically acceptable
formula
acceptable salt
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013501932A
Other languages
English (en)
Japanese (ja)
Other versions
JP6023696B2 (ja
JP2013523705A (ja
Filing date
Publication date
Priority claimed from GBGB1005518.4A external-priority patent/GB201005518D0/en
Priority claimed from GBGB1005522.6A external-priority patent/GB201005522D0/en
Application filed filed Critical
Priority claimed from PCT/GB2011/000497 external-priority patent/WO2011121305A2/en
Publication of JP2013523705A publication Critical patent/JP2013523705A/ja
Publication of JP2013523705A5 publication Critical patent/JP2013523705A5/ja
Application granted granted Critical
Publication of JP6023696B2 publication Critical patent/JP6023696B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013501932A 2010-03-31 2011-03-31 ミョウバンアジュバントおよびミョウバンアジュバント化ワクチンの保存方法 Active JP6023696B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1005518.4A GB201005518D0 (en) 2010-03-31 2010-03-31 Preservation of alum-adjuvanted vaccines
GB1005522.6 2010-03-31
GB1005518.4 2010-03-31
GBGB1005522.6A GB201005522D0 (en) 2010-03-31 2010-03-31 Method for preserving alum-adjuvanted vaccines
PCT/GB2011/000497 WO2011121305A2 (en) 2010-03-31 2011-03-31 Method for preserving alum adjuvants and alum-adjuvanted vaccines

Publications (3)

Publication Number Publication Date
JP2013523705A JP2013523705A (ja) 2013-06-17
JP2013523705A5 true JP2013523705A5 (cg-RX-API-DMAC10.html) 2014-04-24
JP6023696B2 JP6023696B2 (ja) 2016-11-09

Family

ID=43971221

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013501932A Active JP6023696B2 (ja) 2010-03-31 2011-03-31 ミョウバンアジュバントおよびミョウバンアジュバント化ワクチンの保存方法

Country Status (13)

Country Link
US (1) US9101607B2 (cg-RX-API-DMAC10.html)
EP (1) EP2552410B1 (cg-RX-API-DMAC10.html)
JP (1) JP6023696B2 (cg-RX-API-DMAC10.html)
KR (1) KR101819250B1 (cg-RX-API-DMAC10.html)
CN (1) CN102892409B (cg-RX-API-DMAC10.html)
AU (1) AU2011234268B2 (cg-RX-API-DMAC10.html)
BR (1) BR112012025044A2 (cg-RX-API-DMAC10.html)
CA (1) CA2795050C (cg-RX-API-DMAC10.html)
DK (1) DK2552410T3 (cg-RX-API-DMAC10.html)
ES (1) ES2708989T3 (cg-RX-API-DMAC10.html)
GB (1) GB2499480A (cg-RX-API-DMAC10.html)
HU (1) HUE042330T2 (cg-RX-API-DMAC10.html)
WO (1) WO2011121305A2 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011121306A1 (en) * 2010-03-31 2011-10-06 Stabilitech Ltd. Stabilisation of viral particles
HUE033656T2 (en) 2010-03-31 2017-12-28 Stabilitech Ltd Binders for stabilizing virus particles
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
US9588123B2 (en) * 2014-04-11 2017-03-07 Surmodics Ivd, Inc. Compositions and methods for in vitro diagnostic tests including zwitterionic solubilization reagent
GB201406569D0 (en) * 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
AR111760A1 (es) 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
CN113750228B (zh) * 2021-09-25 2024-02-20 大连理工大学 一种冷冻保护剂在铝佐剂中的应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927208A (en) 1973-05-14 1975-12-16 Rit Rech Ind Therapeut Live bovine adenovirus vaccines, preparation thereof and method of vaccination using them
US4631189A (en) 1980-03-10 1986-12-23 Da Vinci Laboratories, a division of FoodScience Corporation N,N-dimethylglycine and use in immune response
JPS6013718A (ja) * 1983-07-05 1985-01-24 Chemo Sero Therapeut Res Inst B型肝炎ワクチン
JPS60193925A (ja) 1984-03-13 1985-10-02 Chemo Sero Therapeut Res Inst 凍結乾燥製剤化ワクチン
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
JPS61189228A (ja) 1985-02-19 1986-08-22 Nippon Sekijiyuujishiya 血液凝固第8因子製剤の製法
US4950596A (en) 1985-03-04 1990-08-21 The Dow Chemical Company Stabilization of intracellular enzymes
JPS6238173A (ja) 1985-08-13 1987-02-19 三菱レイヨン株式会社 抗血液凝固剤
US5169758A (en) 1986-05-02 1992-12-08 Boehringer Mannheim Gmbh Stabilized, NAD(P)H-dependent, soluble nitrate reductase, a process for the preparation thereof and a reagent containing it
NZ221306A (en) 1986-08-15 1990-02-26 Commw Scient Ind Res Org 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof
DE3782737T3 (de) * 1987-08-21 1999-05-20 Imcera Group Inc., Northbrook, Ill. Stabilisierung von Wachstumshormonen.
GB8826429D0 (en) 1988-11-11 1988-12-14 Univ Leeds Ind Service Ltd Enzyme stabilisation systems
ES2113348T3 (es) 1989-08-15 1998-05-01 Massachusetts Inst Technology Composiciones de vacunas estabilizadas.
CA2051092C (en) 1990-09-12 2002-07-23 Stephen A. Livesey Method and apparatus for cryopreparation, dry stabilization and rehydration of biological suspensions
ZA936095B (en) 1992-08-21 1994-03-14 Univ Melbourne Cytokine applications.
AU5543294A (en) * 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
PT1516628E (pt) 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
GB9521806D0 (en) 1995-10-25 1996-01-03 Cortecs Ltd Preservation methods
FR2746109B1 (fr) 1996-03-12 1998-04-17 Rhone Poulenc Rorer Sa Milieu pour la conservation de materiel biologique
CA2242035C (en) 1997-07-01 2004-11-23 Transgene S.A. Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy
EP1032647B1 (en) 1997-11-26 2006-03-29 Universal Preservation Technologies, Inc. Preservation of sensitive biological samples by vitrification
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
EP1977764A1 (en) 1998-11-16 2008-10-08 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
AUPQ347199A0 (en) 1999-10-15 1999-11-11 Csl Limited Novel polypeptide fragments
MXPA02012039A (es) * 2000-06-08 2003-06-06 Powderject Vaccines Inc Composiciones en polvo.
DE10041515A1 (de) 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
US20040110267A1 (en) 2000-12-15 2004-06-10 Stratagene Room temperature stable competent cells
CA2449593A1 (en) 2001-06-08 2002-12-19 Powderject Vaccines, Inc. Spray freeze-dried compositions
US7101693B2 (en) 2001-09-07 2006-09-05 Brigham Young University Plasticized hydrophilic glasses for improved stabilization of biological agents
JP4936618B2 (ja) * 2001-09-21 2012-05-23 株式会社ノエビア 微細エマルション組成物
US20040161776A1 (en) * 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
EP3210624A1 (en) 2002-02-27 2017-08-30 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
EP1539244A1 (en) 2002-06-27 2005-06-15 Novo Nordisk A/S Use of dimethyl sulfone as isotonicity agent
WO2004007537A2 (en) 2002-07-10 2004-01-22 Transgene S.A. Modified adenoviral fiber with ablated to cellular receptors
AU2003272174A1 (en) 2002-10-21 2004-05-04 Biotage Ab Use of osmolytes to heat stabilise luciferase and/or apyrase
CA2508773C (en) 2002-12-10 2013-08-27 Schering-Plough Ltd. Canine rankl and methods for preparing and using the same
US20060247167A1 (en) 2003-09-01 2006-11-02 Novo Nordisk A/S Stable formulations of peptides
US7642077B2 (en) 2003-12-08 2010-01-05 Genencor International, Inc. Biocomposite comprising co-precipitate of enzyme, silicate and polyamine
EP1711619A4 (en) 2003-12-30 2007-04-11 Virumar Pituach Tarkivin Ltd INTEGRATED VIRUS COMPLEXES, METHOD FOR THE MANUFACTURE THEREOF, VACCINES CONTAINING THEM AND METHOD FOR THE USE THEREOF
US8974774B2 (en) 2004-03-03 2015-03-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US20060058238A1 (en) 2004-09-15 2006-03-16 Lee Laurent-Applegate Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same
NZ554426A (en) 2004-10-01 2010-05-28 Ramscor Inc Conveniently implantable sustained release drug compositions comprising at least one non-polymeric excipient
RU2007124933A (ru) 2005-01-28 2009-03-10 Вайет (Us) Стабилизированные жидкие полипептидные составы
GB0502661D0 (en) 2005-02-09 2005-03-16 Stabilitech Ltd A desiccated product
TWI398272B (zh) 2005-03-08 2013-06-11 Intervet Int Bv 化學定義的安定劑
KR20160045151A (ko) 2005-04-08 2016-04-26 아르고스 쎄라퓨틱스 인코포레이티드 수지상 세포 조성물 및 방법
EP2324850A1 (en) * 2005-10-04 2011-05-25 Alk-Abelló A/S Solid vaccine formulation
CN101360821A (zh) 2005-11-21 2009-02-04 圣诺菲·帕斯图尔有限公司 重组病毒的稳定制剂
CA2631292C (en) 2005-11-30 2014-05-06 International Institute Of Cancer Immunology, Inc. Derivatised wt1 cancer antigen peptides and their use
US9393215B2 (en) 2005-12-02 2016-07-19 Novartis Ag Nanoparticles for use in immunogenic compositions
JP2009526856A (ja) 2006-02-15 2009-07-23 イムクローン・リミテッド・ライアビリティ・カンパニー 抗体製剤
ES2286951B1 (es) * 2006-05-26 2008-10-01 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas bioadhesivas para la administracion de moleculas biologicamente activas.
WO2008058035A1 (en) 2006-11-03 2008-05-15 Alphavax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
GB0705245D0 (en) 2007-03-19 2007-04-25 Stabilitech Ltd Stable biological products
DK2829282T3 (en) 2007-03-22 2018-01-02 Univ Colorado Regents Process for preparing an immunologically active adjuvant-linked dried vaccine composition
MX2009012964A (es) * 2007-06-01 2010-01-14 Acologix Inc Formulacion de peptido estable a alta temperatura.
US20090029463A1 (en) * 2007-07-25 2009-01-29 Bioe, Inc. Differentiation of Multi-Lineage Progenitor Cells to Chondrocytes
US20090123436A1 (en) 2007-11-08 2009-05-14 Surmodics, Inc. Cryopreservative compositions and methods
US20110212127A1 (en) 2008-09-24 2011-09-01 Stabilitech Ltd. Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine
GB2479069B (en) 2008-09-24 2012-07-25 Stabilitech Ltd Method for preserving polypeptides using a sugar and polyethyleneimine
CN101670104A (zh) 2009-09-24 2010-03-17 浙江大学 一种含人参皂甙的油佐剂及其制备方法
WO2011121306A1 (en) 2010-03-31 2011-10-06 Stabilitech Ltd. Stabilisation of viral particles

Similar Documents

Publication Publication Date Title
JP2013523705A5 (cg-RX-API-DMAC10.html)
JP2013523704A5 (cg-RX-API-DMAC10.html)
RU2641198C3 (ru) Композиции glp-1 пептидов и их получение
EA201400679A1 (ru) Композиция сухого порошка производного азола для ингаляции
WO2013177172A3 (en) Herpesvirus compositions and related methods
Newcomer et al. Approved and experimental countermeasures against pestiviral diseases: bovine viral diarrhea, classical swine fever and border disease
PE20140845A1 (es) Formulaciones parenterales de vacunas contra los norovirus
RU2015118581A (ru) Лиофилизированные препараты мелфалана флуфенамида
NZ630219A (en) Lyophilization of synthetic liposomal pulmonary surfactant
RU2015136849A (ru) Композиции, содержащие 15-он эпк, и способы их применения
JP2013542263A5 (cg-RX-API-DMAC10.html)
JP6023696B2 (ja) ミョウバンアジュバントおよびミョウバンアジュバント化ワクチンの保存方法
JP2016506905A5 (cg-RX-API-DMAC10.html)
PE20100365A1 (es) Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
RU2016136327A (ru) Композиции на основе мелатонина для парентерального введения
JP6235614B2 (ja) 注射用hpph凍結乾燥粉末注射剤およびその製造方法
WO2009150281A1 (es) Empleo de lauril galato en la prevención y tratamiento de infecciones causadas por el virus de la peste porcina africana (vppa)
JP2016534062A5 (cg-RX-API-DMAC10.html)
CN104857511B (zh) 含人参皂甙的疫苗稀释剂
RU2013157188A (ru) Композиции св-183,315 и относящиеся к ним способы
AR089737A1 (es) Procedimiento de formulacion de una vacuna que contiene al menos dos antigenos susceptibles de adsorberse sobre el oxi-hidroxido de aluminio
RU2016101248A (ru) Лиофилизированные препараты бендамустина гидрохлорида
CN104940149A (zh) 一种复方氨林巴比妥注射冻干粉针剂及其制备方法
CN106540265A (zh) 一种奥格列汀药物组合物及其制备方法
RU2015129081A (ru) Гелевые композиции